The class, defined
Nootropic peptides are short protein chains studied for effects on memory, attention, mood, neuroprotection, and cognitive performance. The category has two distinct origin stories: a Russian and Eastern European pharmaceutical tradition (Semax, Selank, Cerebrolysin, Cortexin, Pinealon) developed since the 1980s and broadly used clinically in those countries, and a Western research-chemical scene (Dihexa, N-Acetyl Semax variants, Adamax) that emerged around 2010. In the US, no nootropic peptide has FDA approval for cognitive indications; cerebrolysin and cortexin have extensive clinical evidence in Alzheimer's, stroke, and brain-injury trials in Europe and Asia but are classified as unapproved drugs in the US. This hub catalogs the 13 nootropic peptides PeptaHub profiles, from the well-characterized Russian clinical peptides to the emerging synthetic angiotensin-IV analogs. A note on Noopept: it's listed here because of category convention, but chemically Noopept is a prolyl-glycine-ethyl-ester racetam derivative — not technically a peptide. We include it for completeness and address the classification ambiguity in the FAQ.
How they work
Nootropic peptides work through several mechanisms that only partially overlap. Melanocortin-derived peptides (Semax, N-Acetyl Semax, Semax 4-7) are Pro-Gly-Pro-stabilized ACTH 4-10 fragments that upregulate BDNF (brain-derived neurotrophic factor) and enhance cortical monoaminergic signaling. Anxiolytic peptides (Selank) are Pro-Gly-Pro-stabilized tuftsin analogs that modulate GABA-ergic and serotonergic systems. Neurotrophic cocktails (Cerebrolysin, Cortexin) are porcine-brain-derived peptide mixtures that supply BDNF-, NGF-, and GDNF-mimetic activity. Angiotensin-IV analogs (Dihexa) activate hepatocyte growth factor / c-Met signaling to promote synaptogenesis and dendritic growth. Peptide bioregulators (Pinealon, Cortagen, Cortexin) are proposed to modulate organ-specific gene expression through direct nuclear interaction. The heterogeneity of the category is a feature, not a bug — different compounds address different cognitive complaints.
Melanocortin-derived (Semax family)
Semax is the heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro — ACTH 4-7 extended with Pro-Gly-Pro for metabolic stability. Upregulates BDNF in the hippocampus within hours of nasal administration, enhances cholinergic and monoaminergic signaling, and has neuroprotective effects in ischemic stroke models. Used clinically in Russia for stroke rehabilitation and ADHD.
Anxiolytic (Selank)
Selank is the heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro — tuftsin 1-4 extended with Pro-Gly-Pro. Anxiolytic without sedation or dependence, modulating GABA-A, serotonin, and enkephalin systems. Used clinically in Russia for generalized anxiety.
Neurotrophic cocktails (Cerebrolysin, Cortexin)
Cerebrolysin is a porcine-brain-derived mixture of low-molecular-weight peptides with BDNF-, NGF-, and GDNF-mimetic activity. 40+ years of clinical use in Europe and Asia; Phase 3 evidence in Alzheimer's disease and stroke rehabilitation. Cortexin is a similar porcine-cortex-derived preparation.
Angiotensin-IV analogs (Dihexa)
Dihexa is a hexapeptide angiotensin-IV analog developed at Washington State University. Activates the HGF / c-Met pathway to promote synaptogenesis and dendritic spine formation. Preclinical data show dramatic memory restoration in scopolamine and aged-rodent models. No human trials yet.
The complete list
13 peptides, ordered by clinical evidence tier. Each entry links to the full profile with mechanism, dosing, side effects, and legal-status detail.
Selank
Approved (Russia, anxiolytic)Synthetic tuftsin analog anxiolytic peptide used clinically in Russia for generalized anxiety. Non-sedating, non-dependence-forming. Modulates GABA, serotonin, and enkephalin systems. Intranasal administration. Popular in Western self-experimental protocols as an anxiolytic nootropic.
Semax
Approved (Russia, stroke/ADHD)ACTH 4-7 heptapeptide upregulating BDNF in the hippocampus. Used clinically in Russia for stroke rehabilitation, ADHD, and cognitive recovery. Intranasal dosing. The most popular nootropic peptide by search volume.
Noopept
Research (racetam-adjacent)N-phenylacetyl-prolyl-glycine ethyl ester — NOT technically a peptide (it's a racetam-adjacent prodrug). Included in this hub because of category convention. Metabolized to cycloprolyl-glycine, which modulates NMDA and AMPA receptors. Russian clinical use for neurotic/cognitive disorders.
Cerebrolysin
Approved (Europe / Asia; Phase 3 AD)Porcine-brain-derived peptide cocktail with BDNF-, NGF-, and GDNF-mimetic activity. 40+ years of clinical use in Europe and Asia for Alzheimer's disease, stroke rehabilitation, and TBI. The nootropic peptide with the strongest human clinical evidence — not FDA-approved in the US but extensively validated elsewhere.
Dihexa
Research (synaptogenic)Angiotensin-IV hexapeptide analog activating HGF / c-Met to promote synaptogenesis and dendritic spine formation. Dramatic memory restoration in preclinical models. No human trials as of 2026 but one of the most promising research nootropics mechanistically.
Pinealon
Research (bioregulator)Tripeptide (Glu-Asp-Arg) bioregulator in the Khavinson family. Proposed to support pineal and cortical function, regulate circadian rhythms, and slow cognitive aging. Russian clinical and research use; limited Western validation.
Cortagen
Research (bioregulator)Tetrapeptide bioregulator targeting cortical cells. Part of the Khavinson bioregulator program. Proposed neuroprotective and cognitive effects in the Russian clinical tradition; limited Western validation.
Cortexin
Approved (Russia, neurological)Porcine-cerebral-cortex-derived peptide preparation used clinically in Russia for stroke, TBI, neurodegenerative disease, and cognitive dysfunction in children. Similar mechanism framework to Cerebrolysin but lower profile internationally.
N-Acetyl Semax
Research (acetylated Semax)Semax analog with N-terminal acetylation for improved metabolic stability. Longer duration than native Semax; same BDNF-upregulating mechanism. Popular in Western self-experimental protocols.
N-Acetyl Semax Amidate
Research (stabilized Semax variant)Further-modified Semax variant with both N-acetylation and C-terminal amidation for maximum stability. Research use only.
Semax 4-7
Research (truncated fragment)Truncated Semax fragment (positions 4-7). Studied mechanistically to identify minimum active sequence. Research use only.
Adamax
Research (ACTH-related)ACTH-related peptide with cognitive and neuroprotective effects in preclinical models. Minimal clinical evidence. Research use only.
Neurotrophin-3
Research (NT-3 growth factor)Member of the neurotrophin family (with NGF, BDNF, NT-4). Supports neuron survival and synaptic plasticity in the peripheral and central nervous system. Preclinical research; no clinical peptide pharmaceutical product.
Compared at a glance
Nootropic peptides have the most uneven evidence base of any pillar. Cerebrolysin has multi-country approval and decades of Phase 3 clinical trials in Alzheimer's disease. Selank and Semax have Russian clinical approval for anxiety and stroke rehabilitation. Dihexa has zero human trials despite being one of the most mechanistically promising candidates. The comparison table orders compounds by clinical approval status first, research maturity next.
| Peptide | Mechanism | Primary use | FDA status | Route | Half-life |
|---|---|---|---|---|---|
| Cerebrolysin | Neurotrophic cocktail | Alzheimer's / stroke | Approved (EU/Asia) | IM / IV | ~hours |
| Selank | Tuftsin / GABA mod | Anxiety | Approved (Russia) | Intranasal | ~1 hour |
| Semax | ACTH 4-7 / BDNF | Stroke / ADHD | Approved (Russia) | Intranasal | ~30 min |
| Cortexin | Cortical peptide pool | Neurological injury | Approved (Russia) | IM | ~hours |
| Noopept | Racetam prodrug | Memory / cognition | Approved (Russia) | Oral | ~30 min |
| Dihexa | c-Met / synaptogenic | Memory restoration | Preclinical | Oral / SC | ~hours |
Cerebrolysin has the strongest human clinical evidence base of any nootropic peptide — multiple Phase 3 trials in Alzheimer's disease and stroke rehabilitation. Selank and Semax have decades of Russian clinical use and the most accessible intranasal dosing. Dihexa is the most exciting preclinical mechanism but lacks human data. Users seeking evidence-based cognitive support with a peptide should look at Cerebrolysin first; users seeking anxiolytic effects should look at Selank; everything else is progressively more experimental.
Safety, side effects & legal status
Nootropic peptides have a generally favorable short-term safety profile in the clinical trials that have been run. Selank and Semax have been used in Russian practice for decades with minimal reported adverse events — headache, mild fatigue, and nasal irritation are the most common complaints. Cerebrolysin has a well-characterized adverse-event profile from its Phase 3 programs, dominated by injection-site reactions and occasional transient confusion. Dihexa's safety in humans is unknown. The broader risk is the supply chain: nootropic peptides sourced from research-chemical vendors bypass pharmaceutical sterility and potency controls, and intranasal preparations carry particular contamination concerns given the direct nose-to-brain pathway. Several nootropic peptides (Cerebrolysin, Selank, Semax) are legally available in other countries but are unapproved in the US; importing them for personal use exists in a regulatory gray zone. PeptaHub's methodology for legal-status review is documented at /methodology.
How to think about this class
Nootropic peptides are the one peptide category where the non-US clinical evidence is genuinely stronger than the US regulatory position. Cerebrolysin has been approved and widely used in Europe and Asia since the 1980s with peer-reviewed Phase 3 evidence in Alzheimer's and stroke. Selank and Semax have decades of Russian clinical practice. That the FDA has not approved them says more about the difficulty of running US registration trials for imported peptide cocktails than about the compounds themselves. Western biohacker adoption of Selank, Semax, N-Acetyl Semax, and Cerebrolysin is not an evidence-free phenomenon — it reflects a gap between pharmaceutical regulation and clinical reality in other countries. The caveat is the supply chain: even when a compound has strong evidence, the research-chemical version of it is not the same product that was studied in trials. Users seeking nootropic peptides should look for pharmaceutical-grade sources (Russian or European compounding pharmacies with legitimate paperwork), understand the legal status in their jurisdiction, and be skeptical of 'research only' US vendors claiming equivalence to clinical-grade product.
Frequently asked questions
A nootropic peptide is a short protein chain — typically 3 to 30 amino acids — studied for effects on memory, attention, or neuroprotection. A nootropic supplement is a much broader category that includes herbal extracts (bacopa, lion's mane), racetams (piracetam, aniracetam), cholinergic compounds (alpha-GPC, CDP-choline), amino acids (L-theanine, tyrosine), and peptides. The peptide subcategory is distinct because of mechanism: peptides interact with specific receptors or signaling pathways in the brain in a way broadly similar to pharmaceutical drugs, while most herbal and amino-acid nootropics work through more diffuse mechanisms. Noopept is sometimes listed as a nootropic peptide but is technically a racetam derivative — we address that in a separate FAQ below.
Selank is primarily anxiolytic (anxiety-reducing) and has been clinically approved in Russia for generalized anxiety. Semax is primarily cognition-enhancing and neuroprotective, with Russian clinical approval for stroke rehabilitation and ADHD. Users seeking focus and cognitive performance typically prefer Semax or one of its more stable variants (N-Acetyl Semax). Users seeking calm without sedation typically prefer Selank. The two can be stacked — Selank in the morning for baseline calm, Semax before cognitive demands — which is a common protocol in Russian clinical practice and Western biohacker self-experimentation.
No nootropic peptide is FDA-approved in the US for any cognitive or neurological indication as of 2026. Cerebrolysin and Cortexin are approved and widely prescribed in Europe, Russia, and parts of Asia. Selank and Semax are approved in Russia. None of these approvals extends to the US, and importing these compounds for personal use exists in a regulatory gray zone. The FDA's position is that these are unapproved new drugs; in practice, enforcement against individual importers is rare but not zero, and commercial sale of any of these compounds as human medications is a violation of federal drug law regardless of 'research only' labeling.
Onset varies dramatically by compound and route. Intranasal Semax or Selank produces subjective effects within 5–15 minutes due to direct nose-to-brain delivery via olfactory and trigeminal pathways. Cerebrolysin IV infusion produces effects over hours to days as the neurotrophic peptides upregulate BDNF and related growth factors. Dihexa (oral) shows effects in preclinical memory-restoration models within 1–2 weeks of daily dosing. Noopept (oral) shows effects within 30–60 minutes acutely and over days of cumulative dosing. Users should not expect a 'same-hour' response from every compound in this class.
Most nootropic peptides are NOT orally bioavailable — digestive proteases break them down before absorption. The exceptions are Noopept (technically a racetam prodrug, not a peptide, which is orally active), Dihexa (engineered for oral bioavailability and BBB penetration), and some bioregulator peptides claimed to survive the gut (evidence thin). Cerebrolysin and Cortexin are administered by intramuscular or intravenous injection. Selank and Semax are intranasal — bypassing the gut entirely and accessing the brain via the olfactory route. Users should check the specific compound's pharmacokinetics before assuming oral dosing is viable.
Noopept (N-phenylacetyl-prolyl-glycine ethyl ester) is routinely listed as a nootropic peptide, but chemically it's a racetam-adjacent prodrug: a phenylacetyl-prolyl-glycine ester that is metabolized to cycloprolylglycine, which then modulates NMDA and AMPA receptors. It contains a dipeptide backbone (prolyl-glycine) but is not a pharmacologically-active peptide in the way Semax or Selank are. We include Noopept on this hub because users searching for 'nootropic peptides' expect to find it — but the more accurate classification is 'racetam-adjacent peptide-derived prodrug.' Russian clinical literature typically groups it with racetams, not peptides.
The short-term safety profiles of Selank and Semax from Russian clinical literature are generally favorable; both have been used for years in clinical practice with minimal reported adverse events. Cerebrolysin has well-characterized long-term safety from multi-year treatment programs in European Alzheimer's clinics. Dihexa and the research-chemical variants have no long-term human safety data. The other risks are independent of the molecule: supply-chain contamination (particularly concerning for intranasal delivery given direct nose-to-brain access), unknown product purity, and potential interactions with other medications. Users considering long-term nootropic peptide use should work with a clinician familiar with the literature and monitor for unusual symptoms.
Sources & further reading
External citations underpinning this page. PeptaHub's full sourcing methodology is documented at /methodology — every claim on this page traces back to one of these references or a linked profile.
- Selank and cognitive enhancement research — PubMed
- Semax neuroprotection mechanisms — PubMed
- Cerebrolysin Alzheimer's clinical trials — PubMed
- Health Fraud Scams — FDA consumer warnings — FDA
- Selank peptide review — Innerbody
See also: glossary, FAQ, about PeptaHub.